Sunesis Pharmaceuticals, Inc. (SNSS) high target is $12 as stated on Yahoo and relatively recent Outperform upgrade from RBC Capital Mkts makes the current $5 valuation absurdly low. Strong buy recommendations 3 with 4 buy recommendations to be found on the Yahoo site help make SNSS a very attractive entry price and all investors can verify the information themselves on Yahoo easily. .
With the recent positive information out of Sunesis Pharmaceuticals, Inc expect a short squeeze as the price climbs. When you see negative postings on your message board just ignore them. You will know this: it's either a short who will be forced to buy to cover or a long wanting in cheap.
Dan Swisher - Chief Executive Officer for Sunesis Pharmaceuticals, Inc. said this: SNS has the cash through 2014, which is beyond several key data milestones.
Further he stated: "Our focus is on Vosaroxin, this is unique anti-cancer drug. We've got full worldwide rights to it and its being pursued in a late-stage hematology indication in relapsed refractory AML, very well powered trial"
"DSMB recommended a sample size increase, which was pre-specified, which indicates that the results were falling into a promising zone."
Many more important quotes that I shall try to post when time permits.